Melan A

A103, Ms

Technische Daten
Change(s) made:Complete revision
Status:In Vitro Diagnostic Use (IVD)
Ig Unterklasse:IgG1
Immunogen:Synthetic peptide
Vorbehandlung:ProTaqs® Antigen Enhancer I (Cat. No. 401602092)
Zelluläre Lokalisation:Cytoplasmic
Kontrolle:Melanoma, normal skin
Synonyme:Melan-A, MART-1, MLANA
Verfügbar in folgenden Ländern:worldwide

Melan A (A103), also known as MART-1 (melanoma antigen recognized by T-cells 1), is an important immunhistochemical marker for the diagnosis of maglignant melanoma. The protein is expressed on the surface of melanocytes and is located in normal skin, retina and nevi.


[1] Fetsch PA, Marincola FM et al. (1999): Melanomaassociated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration. Cancer 87(1): 37-42.
[2] Kageshita T, Kawakami Y et al. (1997): Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother. 20(6): 460-5.
[3] Orosz Z (1999): Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours. Histopath. 34(6): 517-25.
[4] Smith NE, Illei PB, Allaf M et al. (2014): t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 38(5):604-14.
[5] Clarkson KS, Sturdgess IC and Molyneux AJ (2001): The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 54(3):196-200.
[6] Kawakami Y, Eliyahu S, Delgado CH et al. (1994): Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 91(9):3515-9.
[7] Coulie PG, Brichard V, Van Pel A et al. (1994): A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 180(1):35-42.
[8] Yaziji H and Gown AM (2003): Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol. 11(1):11-5.
[9] Ramos-Vara JA, Beissenherz ME, Miller MA et al. (2001): Immunoreactivity of A103, an antibody to Melan A, in canine steroid-producing tissues and their tumors. J Vet Diagn Invest. 13(4):328-32.
[10] Sheffield MV, Yee H, Dorvault CC et al. (2002): Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol. 118(6):930-6.
[11] Shidham VB, Qi D, Rao RN et al. (2003): Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase. BMC Cancer. 3:15.